open access

Vol 11, No 3 (2017)
Review paper
Published online: 2017-12-21
Get Citation

Anxiety and depression in cancer patients — what do we lose?

Szymon Gołota, Katarzyna Białczyk, Zofia Wyszkowska, Alicja Popiołek, Małgorzata Krajnik, Alina Borkowska
Medycyna Paliatywna w Praktyce 2017;11(3):111-117.

open access

Vol 11, No 3 (2017)
Review articles
Published online: 2017-12-21

Abstract

Depression and anxiety is a serious medical problem in about 50% of cancer patients. Depression may worse treatment, course of the illness, psychosocial functioning and quality of patients life and significantly increases mortality as well. The costs of depression is difficulty to account, however in global cost of cancer treatment more and more often medical and social cost of depression is taken into account, however individual patients and caregivers costs are not included in these analyses.

Abstract

Depression and anxiety is a serious medical problem in about 50% of cancer patients. Depression may worse treatment, course of the illness, psychosocial functioning and quality of patients life and significantly increases mortality as well. The costs of depression is difficulty to account, however in global cost of cancer treatment more and more often medical and social cost of depression is taken into account, however individual patients and caregivers costs are not included in these analyses.
Get Citation

Keywords

depression, anxiety, cancer, economic and social lost

About this article
Title

Anxiety and depression in cancer patients — what do we lose?

Journal

Palliative Medicine in Practice

Issue

Vol 11, No 3 (2017)

Article type

Review paper

Pages

111-117

Published online

2017-12-21

Bibliographic record

Medycyna Paliatywna w Praktyce 2017;11(3):111-117.

Keywords

depression
anxiety
cancer
economic and social lost

Authors

Szymon Gołota
Katarzyna Białczyk
Zofia Wyszkowska
Alicja Popiołek
Małgorzata Krajnik
Alina Borkowska

References (44)
  1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6): 593–602.
  2. Kennedy N, Paykel ES. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord. 2004; 80(2-3): 135–144.
  3. Kessler R, Üstün T. The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Method Psych Res. 2006; 13(2): 93–121.
  4. Stein DJ, Hollander E. Współchorobowość depresji i zaburzeń lękowych. Via Medica, Gdańsk 2004.
  5. Jaeschke R, Siwek M, Grabski B. Współwystępowanie zaburzeń depresyjnych i lękowych. Psychiatria. 2010; 7: 189–197.
  6. Murawiec S. Depresja u osób z chorobą nowotworową. Rozpoznawanie i leczenie – aspekty praktyczne. OncoReview. 2012; 2: 201–208.
  7. Nesse R. Emotional disorders in evolutionary perspective. Br J Med Psychol. 2011; 71(4): 397–415.
  8. De Walden-Gałuszko K. Zaburzenia psychiczne w przebiegu choroby nowotworowej. Curr Gynecol Oncol. 2013; 11: 302–321.
  9. International Classification of Diseases. Wyd. 10. WHO, Geneva, 1995.
  10. Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry. 1988; 145(8): 976–981.
  11. Patten SB. Long-term medical conditions and major depression in the Canadian population. Can J Psychiatry. 1999; 44(2): 151–157.
  12. Dudek D, Siwek M. Współistnienie depresji i chorób somatycznych. Psychiatria. 2007; 4: 17–24.
  13. Karakoyun-Celik O, Gorken I, Sahin S, et al. Depression and anxiety levels in woman under follow-up for breast cancer: relationship to coping with cancer and quality of life. Med Oncol. 2010; 27(1): 108–113.
  14. Onitilo AA, Nietert PJ, Egede LE. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry. 2006; 28(5): 396–402.
  15. Chan CM, Wan Ahmad WA, Yusof MMD, et al. Effects of depression and anxiety on mortality in a mixed cancer group: a longitudinal approach using standardised diagnostic interviews. Psychooncology. 2015; 24(6): 718–725.
  16. Pasquini M, Biondi M. Depression in cancer patients: a critical review. Clin Pract Epidemiol Ment Health. 2007; 3: 1–9.
  17. Lueboonthavatchai P. Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. J Med Assoc Thai. 2007; 90(10): 2164–2174.
  18. Krebber AMH, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology. 2014; 23(2): 121–130.
  19. Hofman M, Ryan JL, Figueroa-Moseley CD, et al. Cancer-related fatigue: the scale of the problem. Oncologist. 2007; 12 Suppl 1: 4–10.
  20. Polsky D, Doshi JA, Marcus S, et al. Long-term risk for depressive symptoms after a medical diagnosis. Arch Intern Med. 2005; 165(11): 1260–1266.
  21. Vodermaier A, Linden W, MacKenzie R, et al. Disease stage predicts post-diagnosis anxiety and depression only in some types of cancer. Br J Cancer. 2011; 105(12): 1814–1817.
  22. Cardoso G, Graca J, Klut C, et al. Depression and anxiety symptoms following cancer diagnosis: a cross-sectional study. Psychol Health Med. 2016; 21(5): 562–570.
  23. Paterson C, Robertson A, Nabi G. Exploring prostate cancer survivors' self-management behaviours and examining the mechanism effect that links coping and social support to health-related quality of life, anxiety and depression: a prospective longitudinal study. Eur J Oncol Nurs. 2015; 19(2): 120–128.
  24. Maraste R, Brandt L, Olsson H, et al. Anxiety and depression in breast cancer patients at start of adjuvant radiotherapy. Relations to age and type of surgery. Acta Oncol. 1992; 31(6): 641–643.
  25. Astrup GL, Rustøen T, Miaskowski C, et al. A Longitudinal Study of Depressive Symptoms in Patients With Head and Neck Cancer Undergoing Radiotherapy. Cancer Nurs. 2015; 38(6): 436–446.
  26. Neilson K, Pollard A, Boonzaier A, et al. A longitudinal study of distress (depression and anxiety) up to 18 months after radiotherapy for head and neck cancer. Psychooncology. 2013; 22(8): 1843–1848.
  27. Parker G, Brotchie H. Pancreatic Cancer and Depression: A Narrative Review. J Nerv Ment Dis. 2017; 205(6): 487–490.
  28. Linden W, MacKenzie R, Rnic K, et al. Emotional adjustment over 1 year post-diagnosis in patients with cancer: understanding and predicting adjustment trajectories. Support Care Cancer. 2015; 23(5): 1391–1399.
  29. Schroevers M, Ranchor AV, Sanderman R. Adjustment to cancer in the 8 years following diagnosis: a longitudinal study comparing cancer survivors with healthy individuals. Soc Sci Med. 2006; 63(3): 598–610.
  30. Wilson KG, Chochinov HM, Skirko MG, et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage. 2007; 33(2): 118–129.
  31. Liang X, Margolis KL, Hendryx M, et al. Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. Cancer. 2017; 123(16): 3107–3115.
  32. Liang JW, Cheung YK, Willey JZ, et al. Quality of life independently predicts long-term mortality but not vascular events: the Northern Manhattan Study. Qual Life Res. 2017; 26(8): 2219–2228.
  33. Batty GD, Russ TC, Stamatakis E, et al. Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies. BMJ. 2017; 356: j108.
  34. Majkowicz M. Wybrane problemy psychoonkologii z uwzględnieniem zagadnień psychiatrycznych. Psychiatria w Praktyce Klinicznej. 2008; 1: 57–66.
  35. Siracuse BL, Gorgy G, Ruskin J, et al. What is the Incidence of Suicide in Patients with Bone and Soft Tissue Cancer? : Suicide and Sarcoma. Clin Orthop Relat Res. 2017; 475(5): 1439–1445.
  36. Lavielle-Sotomayor P, Rozen-Fuller E, Bustamante-Rojano J, et al. [Optimism, family cohesion and treatment as predictors of quality of life in blood cancer diseases]. Rev Med Inst Mex Seguro Soc. 2017; 55(4): 456–463.
  37. Kim ES, Hagan KA, Grodstein F, et al. Optimism and Cause-Specific Mortality: A Prospective Cohort Study. Am J Epidemiol. 2017; 185(1): 21–29.
  38. Boursi B, Lurie I, Haynes K, et al. Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients. Eur J Cancer Care (Engl). 2017 [Epub ahead of print].
  39. Mihailovic N, Kocic S, Jakovljevic M. Review of Diagnosis-Related Group-Based Financing of Hospital Care. Health Serv Res Manag Epidemiol. 2016; 3: 2333392816647892.
  40. Dagovic A, Matter Walstra K, Gutzwiller SF, et al. Resource use and costs of newly diagnosed cancer initial medical care. Eur J Oncol. 2014; 19: 166–184.
  41. Kovacević A, Dragojević-Simić V, Rancić N, et al. End-of-life costs of medical care for advanced stage cancer patients. Vojnosanit Pregl. 2015; 72(4): 334–341.
  42. Nabhan C, Feinberg BA. Value-Based Calculators in Cancer: Current State and Challenges. J Oncol Pract. 2017; 13(8): 499–506.
  43. Titler MG, Visovatti MA, Shuman C, et al. Effectiveness of implementing a dyadic psychoeducational intervention for cancer patients and family caregivers. Support Care Cancer. 2017 [Epub ahead of print].
  44. Dockham B, Schafenacker A, Yoon H, et al. Implementation of a Psychoeducational Program for Cancer Survivors and Family Caregivers at a Cancer Support Community Affiliate: A Pilot Effectiveness Study. Cancer Nurs. 2016; 39(3): 169–180.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl